GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arbutus Biopharma Corp (NAS:ABUS) » Definitions » Cyclically Adjusted Price-to-FCF

Arbutus Biopharma (Arbutus Biopharma) Cyclically Adjusted Price-to-FCF : (As of Jun. 06, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Arbutus Biopharma Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Arbutus Biopharma Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Arbutus Biopharma's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arbutus Biopharma Cyclically Adjusted Price-to-FCF Chart

Arbutus Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Arbutus Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Arbutus Biopharma's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Arbutus Biopharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arbutus Biopharma's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Arbutus Biopharma's Cyclically Adjusted Price-to-FCF falls into.



Arbutus Biopharma Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Arbutus Biopharma's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Arbutus Biopharma's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.11/131.7762*131.7762
=-0.110

Current CPI (Mar. 2024) = 131.7762.

Arbutus Biopharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.374 100.560 -0.490
201409 -0.310 100.428 -0.407
201412 -0.321 99.070 -0.427
201503 -0.595 99.621 -0.787
201506 -0.314 100.684 -0.411
201509 -0.061 100.392 -0.080
201512 -0.379 99.792 -0.500
201603 -0.230 100.470 -0.302
201606 -0.337 101.688 -0.437
201609 -0.277 101.861 -0.358
201612 -0.319 101.863 -0.413
201703 -0.386 102.862 -0.495
201706 -0.150 103.349 -0.191
201709 -0.296 104.136 -0.375
201712 -0.191 104.011 -0.242
201803 -0.367 105.290 -0.459
201806 -0.319 106.317 -0.395
201809 -0.243 106.507 -0.301
201812 -0.312 105.998 -0.388
201903 -0.298 107.251 -0.366
201906 -0.314 108.070 -0.383
201909 -0.417 108.329 -0.507
201912 -0.227 108.420 -0.276
202003 -0.228 108.902 -0.276
202006 -0.126 108.767 -0.153
202009 -0.153 109.815 -0.184
202012 -0.174 109.897 -0.209
202103 -0.192 111.754 -0.226
202106 -0.151 114.631 -0.174
202109 -0.159 115.734 -0.181
202112 -0.147 117.630 -0.165
202203 0.138 121.301 0.150
202206 -0.138 125.017 -0.145
202209 -0.124 125.227 -0.130
202212 -0.110 125.222 -0.116
202303 -0.170 127.348 -0.176
202306 -0.123 128.729 -0.126
202309 -0.130 129.860 -0.132
202312 -0.103 129.419 -0.105
202403 -0.110 131.776 -0.110

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Arbutus Biopharma  (NAS:ABUS) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Arbutus Biopharma Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Arbutus Biopharma's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Arbutus Biopharma (Arbutus Biopharma) Business Description

Industry
Traded in Other Exchanges
Address
701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
Executives
Melissa Rewolinski director 9000 STATE ROAD, PHILADELPHIA PA 19136
Karen Sims officer: Chief Medical Officer 701 VETERANS CIRCLE, WARMINSTER PA 18974
J. Christopher Naftzger officer: General Counsel and CCO 633 LOWTHER ROAD, LEWISBERRY PA 17339
Michael J. Sofia officer: Chief Scientific Officer C/O ARBUTUS BIOPHARMA CORP., SUITE 100, 8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Tram Tran director C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974
Roivant Sciences Ltd. 10 percent owner CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Michael J. Mcelhaugh officer: Chief Business Officer C/O ONCORE BIOPHARMA, INC., 3805 OLD EASTON ROAD, DOYLESTOWN PA 18902
Eric Venker director C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
James R Meyers director GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Andrew Cheng director 170 HARBOR WAY, 3RD FLOOR, C/O AKERO THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080
Myrtle S Potter director 10 FINDERNE AVE, BRIDGEWATER NJ 08807
William H. Collier director, officer: President and CEO C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974
Elizabeth Howard officer: Executive VP & General Counsel 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
David C Hastings officer: Chief Financial Officer C/O ARBUTUS BIOPHARMA, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Gaston Picchio officer: Chief Development Officer C/O ARBUTUS BIOPHARMA CORP, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8

Arbutus Biopharma (Arbutus Biopharma) Headlines